Disclosures for "Efficacy of tixagevimab/cilgavimab as pre-exposure prophylaxis to prevent symptomatic COVID-19 infection in Multiple Sclerosis and Related Disorders: a real-world observational study")
-
Dr. Tan has nothing to disclose.
-
Ms. Locke has nothing to disclose.
-
The institution of Dr. Sati has received research support from National Multiple Sclerosis Society. The institution of Dr. Sati has received research support from National Institutes of Health. Dr. Sati has received publishing royalties from a publication relating to health care.
-
Dr. Guerrero has nothing to disclose.
-
The institution of Dr. Sicotte has received research support from Biogen. The institution of Dr. Sicotte has received research support from PCORI. The institution of Dr. Sicotte has received research support from NIH. The institution of Dr. Sicotte has received research support from NMSS. Dr. Sicotte has a non-compensated relationship as a National Medical Advisory Committee Chair with National MS Society that is relevant to AAN interests or activities.
-
The institution of Dr. Al-Louzi has received research support from the National Multiple Sclerosis Society and American Brain Foundation.